Kurse werden geladen...
Prognose
| Kaufen | 6 |
| Halten | 1 |
| Verkaufen | 1 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 3 / 18 |
| Levermann-Strategie | -2 / 13 |
News
Celsion Corporation Announces Company Name Change to Imunon, Inc.
New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines» Mehr auf globenewswire.com
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone» Mehr auf globenewswire.com
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here.» Mehr auf globenewswire.com
Unternehmenszahlen
| (EUR) | Dez. 2024 | |
|---|---|---|
| Umsatz | 698,81k | 89,04% |
| Bruttoeinkommen | 349,41k | 94,41% |
| Nettoeinkommen | −3,90 Mio | 11,82% |
| EBITDA | −3,74 Mio | 31,41% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 12,75 Mio€ |
Anzahl Aktien | 7,43 Mio |
| Dividenden | Nein |
Beta | 2,26 |
KGV (PE Ratio) | 0,00 |
KGWV (PEG Ratio) | −0,04 |
KBV (PB Ratio) | 0,00 |
KUV (PS Ratio) | 17,63 |
Unternehmensprofil
| Name | Celsion Co. |
| CEO | Michael Tardugno |
| Mitarbeiter | 29 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | CLSN |
Assets entdecken
Shareholder von Celsion Co. investieren auch in folgende Assets
